期刊文献+

化疗在胆道恶性肿瘤围手术期应用的意义探讨

Exploring the significance of chemotherapy in the perioperative application of biliary tract carcinomas
原文传递
导出
摘要 胆道恶性肿瘤的恶性程度高,预后极差,根治性切除是目前唯一可能治愈胆道恶性肿瘤的方法。虽然近几年靶向治疗和免疫治疗发展迅速,但化疗在胆道恶性肿瘤围手术期治疗的基石地位依然无法被取代。围手术期化疗目的包括术前缩小肿瘤体积,使患者获得手术切除的机会和提高根治性切除率,以及术后清除残留肿瘤细胞、预防肿瘤复发等。近年来,不断有学者探索了以化疗为基础的联合治疗模式,以增强围手术期治疗效果,进一步改善患者预后。本文从根治性手术围手术期的化疗方案及临床试验进展的角度,探讨了化疗在胆道恶性肿瘤围手术期的应用价值。 Biliary tract cancer is extremely malignant with a poor prognosis.At the moment,the only curative method available is radical resection.Targeted and immunotherapy are currently advancing rapidly,but chemotherapy still holds a key role in the perioperative treatment of biliary cancer.Perioperative chemotherapy aims to decrease tumor volume prior to surgery so that patients can have their tumors surgically removed or have a higher radical resection rate.It also aims to remove any remaining tumor cells after surgery and prevent the growth of new tumors.Combination treatments based on chemotherapy have been increasingly investigated in recent years to improve perioperative care and patient survival.From the point of view of chemotherapy regimens and clinical trial success in the perioperative phase of radical surgery,the value of chemotherapy in the perioperative period of biliary tract cancer was explored in this paper.
作者 汤朝晖 唐玥 于小鹏 陈家璐 全志伟 Tang Zhaohui;Tang Yue;Yu Xiaopeng;Chen Jialu;Quan Zhiwei(Department of General Surgery,Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine,Shanghai 200092,China)
出处 《中华外科杂志》 CAS CSCD 北大核心 2023年第4期277-282,共6页 Chinese Journal of Surgery
基金 国家自然科学基金(81772521) 上海交通大学医学院附属新华医院院级临床研究培育基金(17CSK06) 上海交通大学医学院多中心临床研究(DLY201807)。
关键词 胆道肿瘤 抗肿瘤联合化疗方案 围手术期 辅助治疗 新辅助治疗 转化治疗 Biliary tract neoplasms Antineoplastic combined chemotherapy protocols Perioperative period Adjuvant chemotherapy Neoadjuvant chemotherapy Conversion therapy
  • 相关文献

参考文献3

二级参考文献39

  • 1Jun Sakata,Yoshio Shirai,Toshifumi Wakai,Tatsuya Nomura,Eiko Sakata,Katsuyoshi Hatakeyama.Catheter tract implantation metastases associated with percutaneous biliary drainage for extrahepatic cholangiocarcinoma[J].World Journal of Gastroenterology,2005,11(44):7024-7027. 被引量:31
  • 2田伏洲,石力,汤礼军,汪涛,黎冬暄,邹树,罗皓.胰头癌术前减黄指征的前瞻性研究[J].中华外科杂志,2006,44(23):1614-1616. 被引量:49
  • 3Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet 2014; 383:2168-2179 [PMID: 24581682 DOI: 10.1016/S0140-6736(13)61903-0].
  • 4Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A,Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP,Roughton M, Bridgewater J; ABC-02 Trial Investigators. Cisplatinplus gemcitabine versus gemcitabine for biliary tract cancer.N Engl J Med 2010; 362: 1273-1281 [PMID: 20375404 DOI:10.1056/NEJMoa0908721].
  • 5Fava G, Demorrow S, Gaudio E, Franchitto A, Onori P, CarpinoG, Glaser S, Francis H, Coufal M, Marucci L, Alvaro D, MarzioniM, Horst T, Mancinelli R, Benedetti A, Alpini G. Endothelininhibits cholangiocarcinoma growth by a decrease in the vascularendothelial growth factor expression. Liver Int 2009; 29: 1031-1042[PMID: 19291182 DOI: 10.1111/j.1478-3231.2009.01997].
  • 6Glaser SS, Gaudio E, Alpini G. Vascular factors, angiogenesis andbiliary tract disease. Curr Opin Gastroenterol 2010; 26: 246-250[PMID: 20061944 DOI: 10.1097/MOG.0b013e3283369d19].
  • 7Mius C, Demuth C, Aigner T, Wiedmann M, Wittekind C,Msner J, Hauss J, Witzigmann H. Evaluation of VEGF Aexpression and microvascular density as prognostic factors inextrahepatic cholangiocarcinoma. Eur J Surg Oncol 2007; 33:1025-1029 [PMID: 17400419].
  • 8Thelen A, Scholz A, Weichert W, Wiedenmann B, Neuhaus P,Gessner R, Benckert C, Jonas S. Tumor-associated angiogenesisand lymphangiogenesis correlate with progression of intrahepaticcholangiocarcinoma. Am J Gastroenterol 2010; 105: 1123-1132[PMID: 19997097 DOI: 10.1038/ajg.2009.674].
  • 9Guedj N, Zhan Q, Perigny M, Rautou PE, Degos F, Belghiti J, FargesO, Bedossa P, Paradis V. Comparative protein expression profiles ofhilar and peripheral hepatic cholangiocarcinomas. J Hepatol 2009;51: 93-101 [PMID: 19446907 DOI: 10.1016/j.jhep.2009.03.017].
  • 10Yoshikawa D, Ojima H, Iwasaki M, Hiraoka N, Kosuge T, Kasai S,Hirohashi S, Shibata T. Clinicopathological and prognostic significanceof EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br JCancer 2008; 98: 418-425 [PMID: 18087285].

共引文献109

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部